Comparison Overview

LLX Solutions LLC

VS

Intas Pharmaceuticals

LLX Solutions LLC

1400 Main St, Waltham, Massachusetts, 02451, US
Last Update: 2025-03-05 (UTC)
Between 800 and 900

Strong

LLX Solutions, a biopharmaceutical services company, provides clinical trial design and Protocol development, statistical analysis, programming, data management and Consulting services to the pharmaceutical, biotechnology, and medical device industries. Its team has proven expertise in supporting global clinical trials for different sizes of companies in the United States in various therapeutic categories such as cardiology, oncology, rare disease, medical devices, pain, infectious diseases, neurology, allergy/immunology, endocrinology/metabolism, gastroenterology and pediatrics. LLX Solutionsโ€™ core competencies are its employees. The key members have over 12 years experience in the industry and have built excellent reputations in the companies they severed. They have been working and providing consultant services for various biotech and pharmaceutical companies such as Wyeth/Pfizer, Shire, Genzyme, Altus, Ariad, Synta, Boston Scientific, etc. With this background, LLX Solutions is committed to provide our clients with the highest quality and timely deliverables. We are dedicated to ensuring that our clients will get the best services from us. The company was founded in 2011 and is headquartered in Waltham, Massachusetts.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 83
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Intas Pharmaceuticals

Sarkhej Gandhinagar Highway, Ahmedabad, Gujarat, undefined, IN
Last Update: 2025-05-06 (UTC)

Strong

Between 800 and 900

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, itโ€™s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable โ€œBiosimilars for Billionsโ€ across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 16,979
Subsidiaries: 1
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/llx-solutions-llc.jpeg
LLX Solutions LLC
โ€”
ISO 27001
Not verified
โ€”
SOC 2
Not verified
โ€”
GDPR
No public badge
โ€”
PCI DSS
No public badge
https://images.rankiteo.com/companyimages/intas-pharmaceuticals.jpeg
Intas Pharmaceuticals
โ€”
ISO 27001
Not verified
โ€”
SOC 2
Not verified
โ€”
GDPR
No public badge
โ€”
PCI DSS
No public badge
Compliance Summary
LLX Solutions LLC
100%
Compliance Rate
0/4 Standards Verified
Intas Pharmaceuticals
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for LLX Solutions LLC in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Intas Pharmaceuticals in 2025.

Incident History โ€” LLX Solutions LLC (X = Date, Y = Severity)

LLX Solutions LLC cyber incidents detection timeline including parent company and subsidiaries

Incident History โ€” Intas Pharmaceuticals (X = Date, Y = Severity)

Intas Pharmaceuticals cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/llx-solutions-llc.jpeg
LLX Solutions LLC
Incidents

No Incident

https://images.rankiteo.com/companyimages/intas-pharmaceuticals.jpeg
Intas Pharmaceuticals
Incidents

No Incident

FAQ

Both LLX Solutions LLC company and Intas Pharmaceuticals company demonstrate a comparable AI risk posture, with strong governance and monitoring frameworks in place.

Historically, Intas Pharmaceuticals company has disclosed a higher number of cyber incidents compared to LLX Solutions LLC company.

In the current year, Intas Pharmaceuticals company and LLX Solutions LLC company have not reported any cyber incidents.

Neither Intas Pharmaceuticals company nor LLX Solutions LLC company has reported experiencing a ransomware attack publicly.

Neither Intas Pharmaceuticals company nor LLX Solutions LLC company has reported experiencing a data breach publicly.

Neither Intas Pharmaceuticals company nor LLX Solutions LLC company has reported experiencing targeted cyberattacks publicly.

Neither LLX Solutions LLC company nor Intas Pharmaceuticals company has reported experiencing or disclosing vulnerabilities publicly.

Intas Pharmaceuticals company has more subsidiaries worldwide compared to LLX Solutions LLC company.

Intas Pharmaceuticals company employs more people globally than LLX Solutions LLC company, reflecting its scale as a Pharmaceutical Manufacturing.

Latest Global CVEs (Not Company-Specific)

Description

pwn.college DOJO is an education platform for learning cybersecurity. In versions up to and including commit 781d91157cfc234a434d0bab45cbcf97894c642e, the /workspace endpoint contains an improper authentication vulnerability that allows an attacker to access any active Windows VM without proper authorization. The vulnerability occurs in the view_desktop function where the user is retrieved via a URL parameter without verifying that the requester has administrative privileges. An attacker can supply any user ID and arbitrary password in the request parameters to impersonate another user. When requesting a Windows desktop service, the function does not validate the supplied password before generating access credentials, allowing the attacker to obtain an iframe source URL that grants full access to the target user's Windows VM. This impacts all users with active Windows VMs, as an attacker can access and modify data on the Windows machine and in the home directory of the associated Linux machine via the Z: drive. This issue has been patched in commit 467db0b9ea0d9a929dc89b41f6eb59f7cfc68bef. No known workarounds exist.

Risk Information
cvss4
Base: 9.5
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:H/VI:H/VA:L/SC:H/SI:H/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Adobe Experience Manager versions 11.6 and earlier are affected by a stored Cross-Site Scripting (XSS) vulnerability that could be abused by a low privileged attacker to inject malicious scripts into vulnerable form fields. Malicious JavaScript may be executed in a victimโ€™s browser when they browse to the page containing the vulnerable field. Exploitation of this issue requires user interaction in that a victim must open a malicious link. Scope is changed.

Risk Information
cvss3
Base: 5.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:N
Description

Adobe Experience Manager versions 11.6 and earlier are affected by a stored Cross-Site Scripting (XSS) vulnerability that could be abused by a low privileged attacker to inject malicious scripts into vulnerable form fields. Malicious JavaScript may be executed in a victimโ€™s browser when they browse to the page containing the vulnerable field. Exploitation of this issue requires user interaction in that a victim must open a malicious link. Scope is changed.

Risk Information
cvss3
Base: 5.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:N
Description

Adobe Experience Manager versions 11.6 and earlier are affected by a stored Cross-Site Scripting (XSS) vulnerability that could be abused by a low privileged attacker to inject malicious scripts into vulnerable form fields. Malicious JavaScript may be executed in a victimโ€™s browser when they browse to the page containing the vulnerable field. Exploitation of this issue requires user interaction in that a victim must open a malicious link. Scope is changed.

Risk Information
cvss3
Base: 5.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:N
Description

Adobe Connect versions 12.9 and earlier are affected by a URL Redirection to Untrusted Site ('Open Redirect') vulnerability. An attacker could leverage this vulnerability to redirect users to malicious websites. Exploitation of this issue requires user interaction in that a victim must click on a crafted link.

Risk Information
cvss3
Base: 3.1
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:R/S:U/C:N/I:L/A:N